Payload Information
General Information of This Payload
| Payload ID | PAY0VBLTD |
|||||
|---|---|---|---|---|---|---|
| Name | Cortisol |
|||||
| Synonyms |
cortisol
Click to Show/Hide
|
|||||
| Formula | C21H30O5 |
|||||
| Isosmiles | C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
|
|||||
| InChIKey |
JYGXADMDTFJGBT-VWUMJDOOSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
362.466 |
Polar area |
94.83 |
||
Complexity |
665.525795 |
xlogp Value |
1.7816 |
|||
Heavy Count |
26 |
Rot Bonds |
2 |
|||
Hbond acc |
5 |
Hbond Donor |
3 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Percent Inhibition (%) | -0.09 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.09 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -12 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -15 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -16 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -16.4 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -23 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -3.64 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -8 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 0 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 0 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 0 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0.01 | % |
NIH3T3 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 0.1 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 0.1 | % |
Vero C1008 cells
|
Normal
|
||
| Cellular activity | 0.1 | % |
NIH3T3 cells
|
Normal
|
||
| Cellular activity | 0.15 | ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0.16 | % |
NIH3T3 cells
|
Normal
|
||
| Cellular activity | 0.25 | ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0.54 | ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0.69 | % |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Cellular activity | 0.7 | nM/mg*min | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0.77 | % |
B16-F10 cells
|
Mouse melanoma
|
||
| Cellular activity | 0.85 | ml | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 0.9207 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0.98 | ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | <1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | <1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | <1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | <1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 1.02 | ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 1.04 | % |
B16-F10 cells
|
Mouse melanoma
|
||
| Cell-based Percent Inhibition (%) | 1.1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Median Effective Dose (ED50) | 1.2 | ug ml-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 1.55 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 1.65 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 10.3 | % |
HEK293 cells
|
Normal
|
||
| Maximum Effect (Emax) | 10.5 | % |
INS-1 832/13 cells
|
Rat insulinoma
|
||
| Cell-based Percent Inhibition (%) | 10.83 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 109.6 | mmHg | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 113.79 | % |
CHO cells
|
Normal
|
||
| Median Effective Dose (ED50) | 12 | umol.kg-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 12 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 12.03 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 124 | % |
Sf9 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 14.45 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 156.7 | mmHg | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 16 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 17.2 | mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 17.9 | % |
B16-F10 cells
|
Mouse melanoma
|
||
| Median Effective Dose (ED50) | 18 | mg.kg-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 19 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 2.05 | % |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 2.07 | U |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 2.2 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 2.26 | U |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 2.39 | % |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Cellular activity | 2.46 | % |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 2.5 | U |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 2.66 | U |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 2.68 | U |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 2.69 | U |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 2.72 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 2.97 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Median Effective Dose (ED50) | 20 | ug | Undisclosed | Undisclosed | Undisclosed | |
| Median Effective Dose (ED50) | 20 | ug | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 20.9 | % |
B16-F10 cells
|
Mouse melanoma
|
||
| Cell-based Percent Inhibition (%) | 21 | % |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Median Effective Dose (ED50) | 25 | umol.kg-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 25.1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 28 | umol/L | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 29 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 3 | % | Undisclosed | Undisclosed | Undisclosed | |
| Median Effective Dose (ED50) | 3.09 | ug ml-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 3.13 | % |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Cellular activity | 3.16 | U |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 3.33 | % | Undisclosed | Undisclosed | Undisclosed | |
| Median Effective Dose (ED50) | 3.43 | ug ml-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 3.9 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 30 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 32 | % | Undisclosed | Undisclosed | Undisclosed | |
| 40% Effective Dose (ED40) | 33 | uM kg-1 | Undisclosed | Undisclosed | Undisclosed | |
| 40% Effective Dose (ED40) | 33 | uM kg-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 33 | % | Undisclosed | Undisclosed | Undisclosed | |
| Median Effective Dose (ED50) | 33 | umol.kg-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 35 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 35 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 36 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 36520 | % | Undisclosed | Undisclosed | Undisclosed | |
| Median Effective Dose (ED50) | 38 | umol.kg-1 | Undisclosed | Undisclosed | Undisclosed | |
| Median Effective Dose (ED50) | 38 | umol.kg-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 4 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 4.6 | % |
B16-F10 cells
|
Mouse melanoma
|
||
| Cell-based Percent Inhibition (%) | 42 | % |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Cell-based Percent Inhibition (%) | 42 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 5 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 5.06 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 50 | % | Undisclosed | Undisclosed | Undisclosed | |
| Median Effective Dose (ED50) | 50 | umol.kg-1 | Undisclosed | Undisclosed | Undisclosed | |
| Median Effective Dose (ED50) | 50 | umol.kg-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 51 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 51 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 52.93 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 55 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 55.53 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 56 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 56.33 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 56.6 | % |
B16-F10 cells
|
Mouse melanoma
|
||
| Cell-based Percent Inhibition (%) | 6 | % | Undisclosed | Undisclosed | Undisclosed | |
| Median Effective Dose (ED50) | 6.69 | ug ml-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 6.99 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 60 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 69 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 69 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 69 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 7.09 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Maximum Effect (Emax) | 7.6 | % |
INS-1 832/13 cells
|
Rat insulinoma
|
||
| Cell-based Percent Inhibition (%) | 7.72 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 70 | % |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Cellular activity | 70 | % |
B16-F10 cells
|
Mouse melanoma
|
||
| Maximum Effect (Emax) | 72.5 | % |
INS-1 832/13 cells
|
Rat insulinoma
|
||
| Cellular activity | 73.39 | % | Undisclosed | Undisclosed | Undisclosed | |
| Maximum Effect (Emax) | 75 | % |
INS-1 832/13 cells
|
Rat insulinoma
|
||
| Cell-based Percent Inhibition (%) | 77 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 79 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 8.1 | % |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 80 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 85 | % |
L929 cells
|
Normal
|
||
| Cellular activity | 87.39 | % |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 88.39 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 89.05 | % |
B16-F10 cells
|
Mouse melanoma
|
||
| Median Effective Dose (ED50) | 9 | umol.kg-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 9.14 | % |
B16-F10 cells
|
Mouse melanoma
|
||
| Cell-based Percent Inhibition (%) | 92.1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 92.1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 92.6 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 93.79 | % |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Cell-based Percent Inhibition (%) | 94 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 94.2 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 94.2 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 94.2 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 97 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 97.7 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 97.7 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 97.7 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 98.24 | % |
CHO cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 98.3 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 99 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 99 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 99.52 | % |
NIH3T3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
Macrophage cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 100 | nM |
INS-1 832/13 cells
|
Rat insulinoma
|
||
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
U251 cells
|
Astrocytoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
Hs578T cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SK-OV-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SW620 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SK-MEL-2 cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
CAKI-1 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SK-MEL-28 cells
|
Cutaneous melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SK-MEL-5 cells
|
Cutaneous melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SNB-19 cells
|
Astrocytoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
NCI-H322M cells
|
Minimally invasive lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SF539 cells
|
Gliosarcoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SNB-75 cells
|
Glioblastoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SF268 cells
|
Astrocytoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
A498 cells
|
Renal carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
ACHN cells
|
Renal adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
BT-549 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
HCC 2998 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
HOP-92 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
KM12 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
LOX IMVI cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
M14 cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
Malme-3M cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
NCI-H522 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
RXF 393 cells
|
Renal carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SF-295 cells
|
Glioblastoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
SR cells
|
Leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
TK-10 cells
|
Renal carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
UACC-257 cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
UACC-62 cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
MDA-N cells
|
Breast carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100000 | nM |
UO-31 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 181970.09 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 18706.82 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Activity Concentration (AC50) | 19.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >19952.62 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 2.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
SK-OV-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
B16-F10 cells
|
Mouse melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
COS-7 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
NIH3T3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25.12 | nM |
INS-1 832/13 cells
|
Rat insulinoma
|
||
| Half Maximal Effective Concentration (EC50) | 2511.89 | nM |
INS-1 832/13 cells
|
Rat insulinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 251700 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
HeLa S3 cells
|
Endocervical adenocarcinoma
|
||
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >300000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 316.23 | nM |
INS-1 832/13 cells
|
Rat insulinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 31768.74 | nM |
SN12C cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3260 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 340.41 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3400 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40640 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40640 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40640 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Effective Concentration (EC50) | 41.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 43800 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 51400 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 52430 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 53700 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 53800 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 54230 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 54230 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5500 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 58790 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 58790 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 58790 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 61 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Activity Concentration (AC50) | 631 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 631 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 63860 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 64340 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 64340 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 64340 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Activity Concentration (AC50) | 7609.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 82413.81 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 85640 | nM |
RAW264.7 cells
|
Monocytic-macrophage leukemia
|
||
| Half Maximal Activity Concentration (AC50) | 920 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.631 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.631 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 332 | um | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 66 | um | Undisclosed | Undisclosed | Undisclosed |
Each Antibody-drug Conjugate Related to This Payload